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The BCL11A Transcription Factor Directly Activates RAG Gene
Expression and V(D)J Recombination
Baeck-seung Lee,a* Joseph D. Dekker,a Bum-kyu Lee,a Vishwanath R. Iyer,a Barry P. Sleckman,b Arthur L. Shaffer III,c
Gregory C. Ippolito,a Philip W. Tuckera
Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas, USAa; Department of Pathology and Immunology, Washington University
School of Medicine, St. Louis, Missouri, USAb; Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USAc
Recombination-activating gene 1 protein (RAG1) and RAG2 are critical enzymes for initiating variable-diversity-joining (VDJ)
segment recombination, an essential process for antigen receptor expression and lymphocyte development. The transcription
factor BCL11A is required for B cell development, but its molecular function(s) in B cell fate specification and commitment is
unknown.We show here that the major B cell isoform, BCL11A-XL, binds the RAG1 promoter and Erag enhancer to activate
RAG1 and RAG2 transcription in pre-B cells. We employed BCL11A overexpression with recombination substrates in a cultured
pre-B cell line as well as Cre recombinase-mediated Bcl11alox/lox deletion in explanted murine pre-B cells to demonstrate direct
consequences of BCL11A/RAGmodulation on V(D)J recombination.We conclude that BCL11A is a critical component of a tran-
scriptional network that regulates B cell fate by controlling V(D)J recombination.
Recombination-activating gene endonuclease (RAG) catalyzesthe cleavage phase of V(D)J recombination (1). RAG is en-
coded by two adjacent genes, RAG1 and RAG2, whose products
must interact to form an active endonuclease (2). Both RAG1 and
RAG2 are essential for subsequent B and T lymphocyte develop-
ment (3, 4). In cell-free systems, RAG1 and RAG2 are sufficient to
cleave recombination substrates (1, 5), but in vivo, a number of
additional factors are required for chromatin accessibility of
V(D)J segments and for appropriate completion of the V(D)J
joints (6).
RAG expression occurs at two distinct points during B cell
development: the first phase results in the assembly of the immu-
noglobulin heavy chain (IgH) in pro-B cells, whereas the second
catalyzes Ig light (L) chain assembly in pre-B cells. RAG expres-
sion is tightly regulated at both posttranscriptional and transcrip-
tional levels (6). In addition to the individual promoters forRAG1
and RAG2, the RAG locus encodes at least 5 distal enhancer ele-
ments: the RAG enhancer (Erag), the proximal enhancer (Ep), the
distal enhancer (Ed), and two recently discovered regions termed
Irag1 and Irag2 (7–17) (Fig. 1A). Erag is the strongest enhancer, as
demonstrated by a 5- to 10-fold reduction in RAG expression and
a partial block at the pro-B-to-pre-B transition following targeted
deletion of Erag in mice (10). A number of transcription factors
bind to their corresponding DNAmotifs within single ormultiple
regions within the RAG locus (Fig. 1A), and several of these inter-
actions have been shown to activate RAG transcription (7, 8, 11,
14, 18, 19).
Originally discovered as the gene disrupted by t(2;14)(p13;
q32) translocation in unusually aggressive cases of B cell chronic
lymphocytic leukemia (20–23), the B cell lymphoma/leukemia
11A gene (BCL11A) was subsequently identified as an Kruppel-
like zinc finger oncogene in numerous B cell malignancies (24–
29). Among the five BCL11A isoforms previously identified (23,
30), extra long (BCL11A-XL) (NCBI accession number
AJ404611) is expressed farmore abundantly in hematopoietic lin-
eages (23, 30, 31) (Fig. 1B). All isoforms share a conserved N
terminus and an atypical C2HC zinc finger, which define a “super-
family” of 5 genes essential to myeloid/lymphoid (EHZF), mega-
karyocytic (FOG1 and FOG2), T lymphoid (BCL11B), and B lym-
phoid (BCL11A) development (30) (Fig. 1B). Targeted deletion of
Bcl11a in the mouse indicated that Bcl11a is selectively required
for progression at the earliest stage (pre-pro-B) of B cell progeni-
tor commitment prior to the RAG-dependent formation of pro-B
cells (25). However, a recent study (32) employing a tamoxifen-
inducible global Bcl11a knockout approach reported the loss of all
common lymphoid progenitor (CLP) lineages, including T and
NK cells, while sparing myeloid lineages. While resolution of this
conflict remains, it is clear from these and other studies (33; G. C.
Ippolito et al., submitted for publication) that BCL11A expression
commences prior to that of the RAG transactivators shown in Fig.
1A,whose expression is lost or highly reduced inBcl11a knockouts
(25, 32). Not clear is whether their loss is an indirect result of the
strong progenitor block in Bcl11a-deficient CLP or whether these
factors are direct transcriptional targets of Bcl11a.
Here we identify RAG1 as a direct target of BCL11A-XL.
BCL11A-XL binds within the RAG1 promoter and Erag enhancer
to activate RAG1 and RAG2 transcription in pre-B cells while re-
pressing RAG1 promoter activity in epithelial and fibroblast-de-
rived cell lines. Overexpression of BCL11A-XL in a V(D)J recom-
bination-competent pre-B cell line induces RAG expression and
V(D)J recombination. Cre-mediated deletion of a lox-bearing
Bcl11a locus in cultured pro/pre-B cells abolishes RAG expression
and V(D)J recombination. We show that BCL11A-XL either di-
rectly or indirectly regulates additional RAG activators as well as
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activators of V-J locus accessibility. We propose that, in addi-
tion to its earlier hematopoietic progenitor role, BCL11A is essen-
tial for the pro-B-to-pre-B transition, at least in part, from direct
loss of V(D)J recombination.
MATERIALS AND METHODS
Mice. C57BL/6 mice with loxP sites flanking exons 1 and 2 of Bcl11a were
generated and genotyped as previously described (29, 34, 35; Ippolito et
al., submitted). Mice were bred and housed in the University of Texas
animal research facility. All experiments were approved by the IACUC.
Four- to six-month-old mice were used for bone marrow (BM) cultures.
Cell culture. Human 293T, human Phoenix, mouse NIH 3T3, and
human HeLa cells were maintained in Dulbecco’s modified Eagle’s me-
dium (DMEM) (Gibco BRL) containing 10% fetal bovine serum (FBS)
(HyClone), 100 U/ml penicillin, and 100 g/ml streptomycin. Human
NALM6 pre-B cell and mouse A70 pre-B cell lines were maintained in
RPMI 1640 (Gibco BRL) containing 10% FBS (HyClone), 50M -mer-
captoethanol, 100 U/ml penicillin, and 100 g/ml streptomycin.
Pre-B cells were cultured as described previously (36). B220 cells
were isolated frommouse BMusing B220-labeledmagnetic beads (Milte-
nyi Biotech). Purified cells were overlaid onto an irradiated S17 stromal
cell layer. The cells were maintained in pre-B cell medium (Opti-MEM
medium [Gibco] containing 15% FBS, 50M -mercaptoethanol, 2 mM
L-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, and 5 ng/ml
interleukin-7 [IL-7] [R&D Systems]). Cells were passaged every 3 days
onto a new S17 stromal cell layer.
Retroviruses and transductions. Human BCL11A-XL cDNA was
subcloned into the pXY-IRES-puro (pXY-puro) vector, which was a kind
gift from Louis Staudt, National Cancer Institute (37). Mouse stem cell-
based retroviruses (MIT [mouse stem cell virus–internal ribosomal entry
site–Thy-1.1]) encoding theCre recombinase (MIT-Cre) and the parental
vector (MIT) (8) were gifts of Robert Rickert, Burnham Institute. Mouse
stem cell virus encoding the antiapoptotic factor Bcl-xL (MSCV–Bcl-xL-
Puro) and the stem cell virus encoding the antiapoptotic factor Bcl-xL
were gifts from Robert Rickert, Burnham Institute. Viral DNAs were
transfected into the Phoenix-eco cell packaging line by using Fugene
(Roche) to produce retroviral particles. Viral particles were harvested 48 h
after transfection and centrifuged to remove cell debris. The viral super-
natants were ultracentrifuged at 20,000 rpm for 2 h and resuspended in
the proper amount of serum-free Opti-MEMmedium (Invitrogen).
For pXY-puro viruses, titers were established by infecting NIH 3T3
cells and counting the number of puromycin-resistant cells. Viral particles
were incubated with 10 g/ml of DOTAP liposomal transfection reagent
{N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-
sulfate} (Roche) for 10 min. Various human pre-B and B cell lines were
transduced in 24-well culture plates at 25°C by spin inoculation at 1,000
g for 90 min at 30°C. Forty-eight hours after transduction, cells were
selected in the presence of 0.5 to 2 g/ml of puromycin (Sigma).
FIG1 Schematic representation of theRAG locus andBCL11A superfamily. (A) Transcriptional regulators and binding regions. ThemurineRAG locus is shown
to scale with positions of previously described enhancers (blue arrows), promoters (blue boxes), and exons (black boxes); transcriptional polarity of Rag1 and
Rag2 is indicated with black arrows. Positions of DNA binding sites for transcription factors determined previously (7, 8, 11, 12, 14, 18, 19, 65) or here
(BCL11A-XL) to bind within these regions are indicated by short vertical lines. (B) BCL11A superfamily of transcription factors involved in hematological
malignancy. Each member has a highly conserved N terminus, MSRRK (blue), shown in this study to be essential for BCL11A-XL transcriptional activity. This
is followed by a single, canonical C2HC zinc finger (red), which is followed by one ormore single, double, or triple zinc fingers of the C2H2 type (yellow). BCL11A
and BCL11B, as well as early hematopoietic zinc finger (EHZF) and the friend-of-GATA hematopoietic transcription regulators FOG1 and FOG2, encode zinc
finger proteins with these conserved features, and several have been implicated in malignancy (23, 26, 30, 45, 58).
BCL11A Regulates RAG Transcription
May 2013 Volume 33 Number 9 mcb.asm.org 1769
 o
n
 January 11, 2014 by guest
http://m
cb.asm
.org/
D
ow
nloaded from
 
MIT viruses were preincubated with Polybrene (8 g/ml) and then
diluted 2-fold with Opti-MEM. B220 BM pre-B cells, following culture
(for fewer than 5 passages) as described above, were plated at a density of
1 106 cells/ml and 1 day later were transduced with MSCV–Bcl-xL by
spin inoculation as described above. Following incubation for 1 h at 37°C,
cells were collected, resuspended in pre-B cell medium, and then cultured
for an additional 48 h. Cells were then infected at a high multiplicity of
infection (MOI) with MIT or MIT-Cre. Culture was continued with IL-7
for 3 days and then collected for PCR and reverse transcription-PCR (RT-
PCR) experiments.
Inducible shRNA silencing of BCL11A. Two complementary short
hairpin RNA (shRNA) template oligonucleotides targeting exon 2 of
BCL11A were synthesized and cloned into the pRSMX-PG vector (5)
using HindIII and BglII sites. pRSMX-PG-BCL11A-shRNA retrovirus
was produced in Phoenix cells as described above and used to infect a
Tet-on human B cell line, BJAB (38), which expresses the Tet repressor.
Transduced BJAB cells were selected in the presence of puromycin for 6
days. BCL11A-specific shRNA expressionwas inducedwith different con-
centrations of doxycycline, and samples were tested at regular intervals for
48 h. Levels of BCL11A expression were measured by RT-PCR andWest-
ern blot analysis. The following oligomers were used for the BCL11A
shRNA template: 5=-GATCACCCCAGCACTTAAGCAAATTCAAGAG
ATTTGCTTAAGTGCTGGGGTTTTTTTGGAAA-3= (forward) and 5=-A
GCTTTTCCAAAAAAACCCAGCACTTAAGCAAATCTCTTGAATTT
GCTTAAGTGCTGGGGTG-3= (reverse). BglII and HindIII sites were
used for cloning.
Plasmid constructions. pCMV10–BCL11A-XL and pCMV10–
BCL11A-S were constructed as follows: BCL11A-XL and BCL11A-S were
amplified by PCR with the same forward primer, 5=-GCCAAAGCTTAT
GTCTCGCCGCAAGCAAGGC-3=, and different reverse primers, 5=-
CCCAGGATCCTATTCAGTTTTTATATCATTATTCAAC-3= for the
BCL11A-XL isoform and 5=-CCCAGGATCCTCAAATTTTCTCAGAAC
TTAAG-3= for the S isoform. The PCR products were digested with
BamHI and HindIII and cloned into pCMV10 (Sigma), which contains a
sequence of 3 Flag tag. The pXY-BCL11A-XL plasmid was constructed
by using pCMV10–BCL11A-XL as a template and the following PCR
primers: 5=-CCGGGATCCATGGACTACAAAGACCATGAC-3= (for-
ward) and 5=-GGACGCGGCCGCTATTCAGTTTTTATATCATTATT
C-3= (reverse). The PCR products were digested with BamHI and NotI
and cloned into the pXY-IRES-puro plasmid using BglII and NotI sites.
pEGFPC1-BCL11A and BCL11A-XL-K5N were generated by site-di-
rected mutagenesis using the QuikChange site-directed mutagenesis kit
and protocol from Stratagene. The following primers were used: 5=-CCA
TGTCTCGCCGCAACCAAGGCAAACCCCCAGC-3= (forward) and 5=-
GCTGGGGTTTGCCTTGGTTGCGGCGAGACATGG-3= (reverse). The
deletion mutant pEGFPC1-BCL11ABCL11A-XLdelN80 was constructed
by using PCR with the following primers: 5=-GGCGTCGACAGCGAAC
ACGGAAGTCCC-3= (forward) and 5=-CCCAGGATCCTATTCAGTTT
TTATATCATTATTCAAC-3= (reverse). The PCR products were digested
by using SalI and BamHI and cloned into the plasmid vector pEGFPC1.
The final clones were verified by sequencing.
ChIP and EMSA. Chromatin immunoprecipitation (ChIP) was per-
formed according to instructions provided with the Upstate ChIP kit.
Human pre-B and B cell lines (Nalm6 and Raji) were cross-linked by
incubation at room for 8 min in a final concentration of 1% formalde-
hyde. Fixed cells were washed twice with ice-cold phosphate-buffered
saline (PBS) and lysed in SDS lysis buffer (1% SDS, 10mMEDTA, and 50
mMTris [pH8.1]). Lysateswere sonicated for 0.5min six times to amodal
distribution of1,000 bp. Sonicated chromatin was diluted 10-fold in a
dilution buffer (0.01% SDS, 1.1% Triton X-100, 1.2 mMEDTA, 16.7mM
Tris-HCl [pH 8.1], 167 mM NaCl) and then immunoprecipitated with
purified rabbit IgG or with an anti-BCL11A-XL specific rabbit polyclonal
antibody (BL1797; Bethyl). Antibody-chromatin complexes were washed
with a low-salt wash buffer (0.1% SDS, 1%Triton X-100, 2mMEDTA, 20
mM Tris-HCl [pH 8.1], 150 mM NaCl), a high-salt wash buffer (0.1%
SDS, 1% Triton X-100, 2 mMEDTA, 20mMTris-HCl [pH 8.1], 500mM
NaCl), an LiCl wash buffer (0.25 M LiCl, 1% IGEPAL CA-630 [octylphe-
noxypolyethoxyethanol], 1% deoxycholic acid [sodium salt], 1 mM
EDTA, 10mMTris [pH8.1]), and aTEwash buffer (10mMTris-HCl [pH
8.0], 1 mM EDTA). These complexes were eluted in elution buffer (1%
SDS, 0.1MNaHCO3) and reverse cross-linked at 65°C for 6 to 12 h in the
presence of 0.2MNaCl. After proteinaseK treatment for 1 h at 45°C,DNA
was recovered by using PCR purification columns (Invitrogen) and then
used for PCR analysis. The RAG1 and RAG2 promoters and the Erag
enhancer region were detected by using the following primers: RAG1
forward primer 5=-CATTCTCAGGGAGGGAACTG-3=, RAG1 reverse
primer 5=-GGAGGGCTAACCACAAATGA-3=, RAG2 forward primer 5=-
GTGGTCTCTGCTTCAGGACA-3=, RAG2 reverse primer 5=-AGCAACA
ATGGCAACACAAT-3=, Erag forward primer 5=-GCACTGCAAATGGC
CTGTGAAC-3=, and Erag reverse primer 5=-GAGACCAGAGGGCTTAA
CATTG-3=. ChIP-PCR of RAG1, RAG2, and Erag produced 161-bp, 180-
bp, and 196-bp products, respectively. Thermal cycling conditions were
95°C for 5 min and then 35 cycles at 95°C for 10 s, 55°C for 15 s, 72°C for
10 s, and 72°C for 7min. PCR conditions used for the Erag enhancer were
95°C for 5 min and then 35 cycles at 95°C for 1 min, 57°C for 1 min, 72°C
for 1 min, and 72°C for 7 min.
To construct electrophoretic mobility shift assay (EMSA) probes, the
proximal promoter region (243 bp upstream of the transcriptional start
site [TSS] [243] to 123 bp downstream of the TSS [123]) of themouse
RAG1 gene (39) was amplified by PCR using RAG1 forward primer 5=-C
ATTCTCAGGGAGGGAACTG-3= and RAG1 reverse primer 5=-GGCAA
AGTGTGTTCTCTGCTC-3= from plasmid template R1P-Luc. The Erag
enhancer (10) probe was a 196-bp fragment extending from the KpnI site
to the end of region A (11). The probe for the distal promoter region of
Rag1 (positions713 to563) was generated by KpnI-HindIII digestion
of plasmid 713-R1P-Luc. Probes were end labeled with 32P by using
polynucleotide kinase and then purified by using Bio-Spin columns (Bio-
Rad) and 6% native gels. Reaction mixtures consisted of 5 to 10 g of
nuclear extract prepared from various B cell lines, probes, and a binding
buffer (20mMHEPES [pH 7.9], 40mMKCl, 6mMMgCl2, 1mMdithio-
threitol [DTT], 0.1% NP-40, 3 mg/ml bovine serum albumin, 10% glyc-
erol, 2% Ficoll, 50 g/ml of sonicated salmon sperm DNA, and protease
inhibitor cocktail). The binding mixture was incubated at room temper-
ature for 30 min. For the antibody binding competition assays, 100 ng of
BCL11A polyclonal antibody (BL1797) or of monoclonal antibody
(MAb)mAb123 (40) or an equal amount of a control rabbit IgG antibody
or an irrelevant tubulin MAb was added at the initiation of each binding
reaction. Cold competitions were carried out with increasingmolar ratios
of wild-type (5=-GGTCAGTCCGTTTCCAACTTCCTCCAGCAG-3=)
and mutant (5=-GGTCAGTCCGTGGGTAAGCCCCTCCAGCAG-3=)
duplexed, gel-purified oligonucleotides spanning the putative BCL11A
binding site at Erag nucleotide (nt) positions 121 to 131. (Mixtures were
fractionated on 6.0 to 7.5% nondenaturing acrylamide. The gels were
dried and analyzed by using a PhosphorImager [Molecular Dynamics].)
Luciferase assays. Pre-B cells (A70, A70-BCL11A-XL, and A70-
BCL11A-XL-K5/A) and non-B cells (293T, COS-7, and NIH 3T3) were
plated at1106 cells per well in 12-well plates. Twenty-four hours later,
pre-B cells were transiently transfected with 1 g of firefly luciferase re-
porters (detailed in Fig. 6), 5 ng of Renilla luciferase, and, in some cases, 1
g of pFLAG-MTA1 using the mouse B cell Nucleofector kit (VPA-1010,
program Z-01) and cell line kit (VCA-1003, program M13) according to
the manufacturer’s recommended protocol. The transfection efficiency
(determined by pEG-GFP transfection in parallel assays) achieved in
pre-B cells was 40 to 50%. Empty vector plasmid DNA was used to keep
the total amount of transfected DNA equal under each experimental con-
dition.
Non-B cells were transiently transfected with 1 g of the firefly lucif-
erase reporter constructs (detailed in Fig. 6), 5 ng ofRenilla luciferase, and
either wild-type BCL11A-XL or BCL11A-XL-K5/A expression vectors
over a concentration range of 0.1 to 1.5 ng. An empty pCMV10 construct
Lee et al.
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was then added to each transfection mix to ensure that final DNA con-
centrations were equal.
Forty-eight hours after transfection, cells were harvested for dual-lu-
ciferase reporter assays (Promega), using cell lysis and luciferasemeasure-
ments as described in the manufacturer’s manual. Values were normal-
ized by determining the ratio of firefly to Renilla luciferase for each
transfection. To determine fold expression, the firefly/Renilla ratio in ex-
perimental samples (i.e., those with BCL11A-XL overexpression, the Re-
nilla vector, and its respective firefly luciferase RAG reporter) was com-
pared to the firefly/Renilla ratio from basal luciferase expression samples
(i.e., those without BCL11A-XL overexpression). Western blotting con-
firmed that BCL11A-XL protein lysate levels corresponded to the concen-
tration of input DNA.
Microarray. Briefly, 3g ofmRNA of various human pre-B and B cell
lines was reverse transcribed by using aminoallyl UTP/deoxynucleoside
triphosphates (dNTPs). Synthesized cDNA was hydrolyzed and column
purified (Invitrogen). Each cDNA sample was coupled with cy3 or cy5
dye,mixed, and hybridized to full genomehuman array slides.Microarray
slides were scanned by using a GenePix 4000a microarray scanner.
Flow cytometry. A70-INV and A70-INV-BCL11A-XL cells were in-
cubated in the absence or in the presence of 3MSTI571 (Novartis) for 3
days. The harvested cells were washed two times with ice-cold PBS and
resuspended in PBS at a concentration of1 106 cells/ml. A minimum
of 5,000 cells per sample was used for each analysis. Flow cytometry (BD
FACSCalibur flow cytometry system) was used to analyze the samples for
green fluorescent protein (GFP)-positive signals. Cell debris and dead
cells were excluded from the analysis by forward- and side-scatter analysis.
The parental A70-INV cells were used for GFP gating. Data were analyzed
by using Cell Quest software. Bcl11aL/L/MIT and Bcl11aL/L/MIT cultured
bone marrow cells were costained under similar conditions and stained
with fluorescein isothiocyanate (FITC)-conjugated anti-Thy-1.1 (T1-A3;
Abcam) andR-phycoerythrin-conjugated anti-B220 (RA3-6B2; BDPhar-
mingen). For DNA content/cell cycle analysis, cells were incubated for 15
min at 20°C in 300 to 500 l propidium iodide–Triton X-100 staining
solution (catalog number 11348639001; Roche). Data were acquired as
described above.
Genomic DNA isolation and Southern blotting. A DNeasy tissue kit
(Qiagen) was used to isolate genomic DNA from cultured A70-INV cells
or bone marrow-derived B220 pre-B cells according to previously re-
ported protocols, with some modifications (39, 41). For genomic PCR,
100 to 200 ng of genomic DNA was PCR amplified and then subjected to
electrophoresis in agarose gels. The scheme for detected inversion of the
ectopic locus by GFP flow cytometry or by PCR is illustrated in Fig. 5C.
PCR products were transferred onto a nylonmembrane for Southern blot
analysis. A J2-2 oligonucleotide probe was end labeled with T4 polynu-
cleotide kinase. Southern blots were prehybridized overnight and then
hybridized with probes for 3 h at 50°C in Ultra-hyb solution (Ambion).
Blots were washed once at room temperature and twice at 50°C in 2 SSC
(1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate)–0.1% SDS for 30
min each, and signals were detected by using a PhosphorImager (Molec-
ular Dynamics). The following primers were used for PCR detection of
inversion: 5=-CACAACATCGAGGACGG-3= (pA) and 5=-GCACCACTT
TCTTTCCCTGA-3= (hCD4R). The primers for endogenous rearrange-
ment and blotting were as follows: Vcon forward primer 5=-CCGAATTC
GSTTCAGTGGCAGTGGRTCWGGTAC-3=, J2-1 reverse primer 5=-G
GTTAGACTTAGTGAACAAGAGTTGAGAA-3=, J2-2 probe 5=-CAAG
AGTTGAGAAGACTACTTACGTTTT-3=, and J2-2 reverse primer 5=-T
GCCACGTCAACTGATAATGAGCCCTCTC-3=. The amplification
conditions were 30 cycles at 94°C, 90 cycles at 60°C, and 60 cycles at 72°C.
Semiquantitative RT-PCR. RNA purification was performed with
TRIzol LS according to themanufacturer’s instructions (Invitrogen). Pel-
lets were resuspended in RNase-free water. For first-strand synthesis by
reverse transcription, we used the SuperScript II First kit (Invitrogen).
Serial dilutions of template cDNA were subjected to 30 cycles of PCR by
using amplification conditions reported previously (7, 8, 11, 14, 15,
19, 30).
Quantitative PCR. Either genomic DNA or cDNA transcribed with
the SuperScript RT III-based protocol mentioned above was analyzed by
quantitative real-time PCR performed on an Applied Biosystems ViiA7
thermocycler using Sybr green chemistry (Applied BioSystems Sybr green
or Quantus Sybr green). All assays were performed in triplicate and ana-
lyzed by the standard curvemethodwith normalization to the housekeep-
ing gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (42, 43).
Oligonucleotide primers. Primers used for semiquantitative and
quantitative PCR (in the 5=-to-3= orientation) were as follows: RAG1-F
(CCAAGCTGCAGACATTCTAGCACTC), RAG1-R (CTGGATCCGGA
AAATCCTGGCAATG), RAG2-F (CACATCCACAAGCAGGAAGTAC
AC), RAG2-R (GGTTCAGGGACATCTCCTACTAAG), IRF4-F (CCAC
GGACACACCTATGATG), IRF4-R (GGTCTGGAAACTCCTCACCA),
IRF8-F (GGGCTGCCTAAGTTGTATG), IRF8-B (ACCACCCTGCTGT
CAGGTAG), Spi-B-F (GAGGACTTCACCAGCCAGA), Spi-B-R (TGAG
TTTGCGTTTGACCTTG), gVk-F (CCACATGCCTTTCTTCAGGGAC
AAGTG), gVk-R (TTATGTCGTTCATACTCGTCCTTGGTC), Foxp1-F
(AAGGGGCAGTATGGACAGTG), Foxp1-R (CCCAGAGGTTCACTCC
ATGT), BCL11A-F (CCCAGAGTAGCAAGCTCACC), BCL11A-R (CAG
GATCCTATTCAGTTTTTATATCATTATTC), FoxO1-F (CAAAGTAC
ACATACGGCCAATCC), FoxO1-R (CGTAACTTGATTTGCTGTCCT
GAA), E2A-F (TTGTGGACATTTTCTAGGCAG), E2A-R (ATGTGTGG
TGGCCCACACTTG), Pax5-F (AGACAGGAAGCATCAAGCCTG),
Pax5-R (CAGCGAGGCCATGGCTGAATA), Vpre-B-F (GTAGAGGCA
TGCCAGCCGGTGCT), Vpre-B-R (CTTGAAGCTTTCGAGGGACACG
TGT), 5-F (ACTGTCGGATCCTCGCAGAGCAGG), 5-R (CAGTCAA
GCTTCTATGAACATTCT), GAPDH-F (ACTTTGTCAAGCTCATTT
CC), GAPDH-R (TGCAGCGAACTTTATTGATG), VCON-F (CCGAAT
TCGSTTCAGTGGCAGTGGRTCWGGTAC), and J2-1-R (GGTTAGA
CTTAGTGAAGAGTTGAGAA).
Biochemistry. Western blotting was carried out as previously de-
scribed (30). The following dilutions were used for each antibody: 1:5,000
for Flag (Sigma), 1:2,000 for -tubulin (Santa Cruz), 1:2,000 for RAG1
(catalog number 554116; Pharmingen), 1:3,000 for BCL11A-XLc
(BL1797; Bethyl), 1:2,000 for BCL11A-mAB123 (prepared in our labora-
tory), 1:1,000 for lamin B (Santa Cruz), and 1:1,500 for cytochrome c
(catalog number 556432; Pharmingen).
Nuclear subcellular fractionation was carried out with a minor mod-
ification (9) of a procedure described previously by Reyes et al. (44).
Cytoplasmic contamination into the nuclear fraction will result in con-
tamination within the soluble NP fraction (2). Lamin B signals were used
to evaluate contamination of nuclear fractions into the cytoplasmic frac-
tions (44). Cytoplasmic contamination was also assessed by anti-cyto-
chrome cWestern analysis.
RESULTS
BCL11A-XL modulates RAG expression. As an initial approach,
we used microarrays to identify genes that are deregulated by
BCL11A-XL overexpression in mature B (Raji, Ramos, OCI-LY7,
and BJAB) and pre-B (NALM6) human cell lines. B cell lines were
transduced with pXY-puro (mock control) or with the same virus
containing an N-terminally Flag-tagged, full-length BCL11A-XL
cDNA. Among the 17,856 clones tested, 43 clones, which repre-
sent 39 genes, showed alterations of at least 2-fold in all four cell
lines. As expected from previous studies of BCL11A function,
most of the transcripts were downregulated (data not shown).
Among the 11 upregulated genes, RAG1 was consistently ob-
served, even though the basal transcript levels in the mature lines
were near baseline (Fig. 2A).
We created a stable BCL11A-XL-overexpressing line of
NALM6 pre-B cells and checked RAG1 and RAG2 expression by
semiquantitative RT-PCR. As shown in Fig. 2B, both RAG genes
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were significantly upregulated. As a complementary approach, in-
ducible short hairpin RNA (shRNA) interference was used to spe-
cifically target a region (exon 2) common to all BCL11A isoforms.
As shown in Fig. 2C, we observed a robust knockdown of BCL11A
transcripts as well as a corresponding reduction in both RAG1 and
RAG2 transcripts by the end of the first 24 h of induction.
BCL11A is recruited to the RAG1 promoter and to the Erag
enhancer in vivo and in vitro. Chromatin immunoprecipitation
(ChIP) was employed to test whether BCL11A-XL is recruited to
the RAG promoters or RAG enhancer loci in human pre-B cell
(NALM6) and mature B cell (Raji) chromatin. Specific sets of
primers were designed within the upstream 1-kb region of each
promoter and within the 0.8-kb first one-third of the Erag en-
hancer. ChIP-PCR demonstrated that the RAG1 promoter and
Erag, but not the RAG2 promoter or the Ep or Ed enhancer, were
enriched in pulldowns with anti-BCL11A but not with control
antibody (Fig. 3A and data not shown). This indicated that
BCL11A-XL is recruited either directly or indirectly to the proxi-
mal promoter of RAG1 and to the RAG enhancer in vivo.
EMSAs were performed to validate and extend the results
shown in Fig. 3A. A 32P-labeled 196-bp probe extending from the
5= end to the 3= end of region A of Erag (11) was incubated with
nuclear extracts prepared from Raji B cells, and several complexes
were observed (Fig. 3B). A slowly migrating species (boxed in Fig.
3B to E) was specifically abolished by pre- or postincubation with
anti-BCL11Amonoclonal antibody (Ab123) or a polyclonal anti-
body specific for the BCL11A-XL C terminus (Fig. 3B, lanes 3 and
5) but not with control antibodies (Fig. 3B, lanes 4 and 6). Specific
double-stranded-oligonucleotide competition (Fig. 3B, compare
lanes 8 to 10 to lanes 11 and 12) identified a BCL11A binding site
that closelymatched (8/10) the BCL11A consensus determined by
high-resolution, genome-wide ChIPseq derived publically from
the human B cell lymphoma GM12728 (28) (Fig. 3F). This site is
overlapped frompositions2 to4with a consensus binding site
(GAGGAA) for PU.1, an essential myeloid/lymphoid transactiva-
tor, which was shown to bind to the Ep element (Fig. 1A) (16).
Accordingly, we observed partial ablation of the BCL11A complex
with anti-PU.1 (Fig. 3B, lane 7), suggesting that these factors
might act in concert or in opposition at this apparent composite
site. Using a similar approachwith nuclear extracts prepared from
pre-B (NALM6) (Fig. 3C, lanes 2 to 7), pro-B (HAPTL1) (Fig. 3C,
lanes 8 to 13, and D, lanes 2 to 10), and mature B (Raji) (Fig. 3C,
lanes 14 to 19, and E, lanes 2 to 4) cell lines, we validated two
similarlymigrating BCL11A complexes within the distal (nt426
to 416) and proximal (nt 207 to 197) regions of the RAG1
promoter (Fig. 3C to E). Ablation as opposed to supershifting of
complexes suggested that both anti-BCL11A antibodies interfere
withDNAbinding, leading to dissociation of BCL11A-DNA com-
plexes. Both proximal anddistal BCL11A-XLbinding sites arewell
within the ChIP region shown in Fig. 3A. Further consistent with
our ChIP-PCR results, no binding to RAG2 promoter probes was
observed (data not shown), nor did we detect specific binding
when recombinant, in vitro-translated BCL11A-XL, -L, or -XSwas
employed in the EMSAs (data not shown). This suggested that
BCL11A-XL binding requires a complex provided by another fac-
tor(s), potentially PU.1, present in nuclear extracts in pro-B,
pre-B, and mature B cells.
BCL11A-XL transactivates RAG1 and Erag-RAG2 transcrip-
tion in pre-B cells. Transformation of murine fetal liver or bone
marrow B cell progenitors by the Abelson murine leukemia virus
arrests cells at the early (large) pre-B cell stage with low to negli-
gible Rag1 andRag2 expression levels (6). One such line, A70 (39),
expresses negligible levels of BCL11A (Fig. 4A) and was employed
for functional evaluation of Rag activation. Stable BCL11A-XL
overexpression, achieved by retroviral transduction, induced high
levels of endogenousRag1 andRag2 (Fig. 4A). These cells (termed
A70-BCL11A-XL) were compared to the parental BCL11A-XL-
negative A70 line following transient transfection with luciferase
FIG2 BCL11A-XL regulates RAG expression. (A)Microarray identification of RAG1upregulation. The indicated humanB cell lines were stably transducedwith
a BCL11A-XL (XL) retrovirus or with the pXY-puro empty vector. Expression profiling was performed inmultiple (n	 4) independent experiments tracked by
multiple probe elements spotted per microarray. Shown are the 11 transcripts upregulated by minimally 2-fold relative to the vector control in all cell lines. (B)
Overexpression of BCL11A-XL upregulates RAG.HumanNALM6pre-B cells were stably transducedwith BCL11A-XL or the pXY-puro virus control (V). (Left)
Western blot in which Flag-BCL11A indicates anti-Flag detection of viral BCL11A-XL expression. Total BCL11A, anti-BCL11A-XL MAb detection; Tub,
anti--tubulin control. (Right) RT-PCRdemonstrates upregulation of RAG1 andRAG2. Serial template dilution (3-fold) (indicated by triangles) confirmed that
RT-PCR was semiquantitative. GAPDH was used as a loading control. (C) Inducible shRNA knockdown of BCL11A-XL reduces RAG expression. BJAB B cells
were stably transduced first with a retrovirus expressing the bacterial tetracycline repressor (TETR) and the blasticidin resistance gene and then with a
pRSMX-PG retrovirus containing shRNA targeted to exon 2 of BCL11A-XL under the control of a modified H1 promoter containing binding sites for the
tetracycline repressor (38). Significant downregulation of BCL11A-XLprotein (left) and transcript (right) with concomitant downregulation of RAG1 andRAG2
was observed 24 h following addition of the tetracycline analogue doxycycline (Dox).
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(Luc) reporter constructs that were previously shown (10, 17) to
recapitulate authentic activities of the proximalRag1 (243-R1p-
Luc) andRag2 (279-R1p-Luc) promoters in the absence or pres-
ence of the full 2.3-kb Erag enhancer. A70-BCL11A-XL firefly
luciferase activities were normalized relative to cotransfected
Renilla luciferase activities and plotted as fold activation over a
promoterless luciferase control.
As shown in Fig. 4B, BCL11A-XL only modestly increased
Rag1proximal promoter-driven transcription levels (average, 1.6-
fold). Appending Erag to the reporter provided an 4-fold en-
FIG 3 BCL11A is recruited to the RAG1 promoter and the Erag enhancer in vivo and in vitro. (A) ChIP-PCR identifies the RAG1 promoter and Erag enhancer
as targets for BCL11A binding. A rabbit polyclonal antibody (BL1797; Bethyl) specific to the BCL11A-XL C terminus (BCL11A-XL Ab) was used to immuno-
precipitate NALM6 pre-B cell chromatin. The samples were reverse cross-linked, purified, and analyzed by semiquantitative PCR using primers that amplify
regions within the proximal RAG1 and RAG2 promoters and within the Erag enhancer. Specific enrichment was observed for the RAG1 promoter and the Erag
enhancer (lanes 3 and 9) but not for the RAG2 promoter (lane 6). PCRs from 1% input were used as positive controls (lanes 1, 4, and 7). Purified rabbit IgG
antibodies (con Ab) did not immunoprecipitate target DNA significantly (lanes 2, 5, and 8). (B) BCL11A binds to the Erag enhancer in vitro. A 196-bp probe
extending from the 5= boundary (KpnI site) to the end of region A of Erag (11) was labeled with 32P and then incubated with nuclear extracts prepared from the
Raji B cell line. Specificity of bindingwas tested by further incubation of the indicated probe-nuclear extractmixtureswith anti-BCL11A-XL (BL1797)C-terminal
polyclonal antibody (C-Term Ab), with monoclonal antibody (mAb123 Ab), with monoclonal anti-PU.1 antibody (
-PU.1), or with control polyclonal (
-IgG
Ab) andmonoclonal (
-TubulinAb) antibodies employed at the same concentrations. Cold competitions employed double-stranded 30-mers of wild-type (cold
oligonucleotide) and mutated (cold mutant oligonucleotide) oligonucleotides spanning the putative BCL11A binding site at nt 121 to 131. Triangles represent
molar excesses of 10-, 50-, and 100-fold relative to labeled probe. Complexes were resolved on native 6% gels, with specific binding highlighted by boxes. (C and
D) BCL11A binds to a consensus site within the distal region (positions426 to416) of theRAG1 promoter. The probe was a 300-bpKpnI-XhoI fragment. (E)
BCL11A binds to a consensus site within the proximal region (positions207 to197) of the RAG1 promoter. The probe was a 263-bp PCR product spanning
positions228 to35. (F) Alignment of BCL11A binding sites determined in this study with consensus of the top 500 peaks determined by ENCODE ChIPseq
in GM12878 human B cell lymphoma (28).
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hancement in A70, which was doubled in the A70-BCL11A-XL
transductants.When theRAG1 promoter was extended to include
the more distal BCL11A-XL binding region located at position
640 (719-R1p-Luc), we observed an3-fold increase above
the levels observed for the proximal Rag1 promoter alone and an
12-fold increase in the presence of Erag. Consistent with the
EMSA and ChIP data, no effect of BCL11A-XL overexpression on
Rag2 proximal promoter-luciferase activity alone was observed.
However, inclusion of Erag on the construct resulted in an 3-
fold increase in the absence of BCL11A-XL and an 14-fold in-
crease in Rag2 reporter activity in the presence of BCL11A-XL
overexpression (Fig. 4B).
The N termini of several members of the BCL11A superfamily
(30) constitute the transactivation domain, and K5 was shown to
be essential in several cases (26, 45) (Fig. 1B). Activation of all
reporter activities by BCL11A-XL was abrogated by the K5/A sub-
stitution (Fig. 4B). Collectively, the data indicate that BCL11A-XL
acts at the Rag1 promoter, primarily through a distal binding site,
whereas BCL11A-XL activates Rag2 transcription exclusively via
Erag binding.
Enforced expression of BCL11A in non-B cells represses
RAG1-mediated transcription. The above-described results,
along with the PU.1 DNA binding cooccupancy implications of
Fig. 3 and previous observations that RAG1 expression is not lym-
phoid restricted (9, 12), prompted us to test the cell type specificity
of BCL11A-mediated RAG transactivation. Contrary to what was
observed for pre-B cells, BCL11A-XL overexpression in 293T cells
led to strong repression (5- to 6-fold) of both proximal (243-
R1p) and distal (719-R1p) Rag1 promoter-driven activities,
whereas RAG2 and Erag-RAG2 luciferase activities were unaf-
fected (Fig. 4B). This indicated that the more proximal BCL11A
binding site within the Rag1 promoter is sufficient for targeting
FIG 4 RAG transcriptional reporter activity is activated in pre-B cells but repressed in non-B cells following BCL11A-XL overexpression. (A) Establishment of
stable overexpression. A70 pre-B cells were transduced with pXY-IRES-puro (V) or pXY-BCL11A-XL (XL) and selected with 1 g/ml of puromycin for 6 days.
Triangles represent 5-fold dilutions of cDNA. (B) BCL11A-XL transactivates RAG1 promoter-driven and Erag-RAG2 promoter-driven transcription in A70
pre-B cells but represses RAG promoter-driven activity in 293T epithelial cells. A70 and 293T cells, stably transduced with pXY vector only (V), BCL11A-XL, or
BCL11A-XL mutated at an essential N-terminal K5 (XL-K5/A), were transiently transfected, as described in Materials and Methods, with the indicated firefly
luciferase constructs and aRenilla luciferase control. Cells were harvested 40 to 48 h later, and firefly luciferase values were normalized toRenilla luciferase values.
The ratio is expressed as fold changes by arbitrary assignment of a value of 1.0 for the empty vector (pXY-IRES-puro for pre-B cells or pCMV10 for non-B cells).
Fold changes are plotted on the y axis, with the magnitude of activation denoted by increasing positive values and repression indicated by negative values. Error
bars indicate standard deviations of 3 to 5 independent experiments. (C)Wild-type BCL11A-XL and the BCL11A-K5/Amutant localize indistinguishably within
the nuclear matrix of paraspeckles in pre-B and non-B cells. (Top) Fixed amounts of GFP–BCL11A-XL and GFP–BCL11A-XL-K5/A were imaged following
transient transfection into 293T cells. Ectopically transduced A70-BCL11A-XL cells were stained with anti-BCL11A monoclonal antibody Ab123. (Bottom)
Biochemical fractionation of transiently transfected 293T cells with the indicated wild-type or mutant BCL11A-XL constructs. Equivalent amounts of cytoplas-
mic (C), soluble nuclear (NP), chromatin (C), and nuclear matrix (NM) fractions were fractionated (44) on SDS-PAGE gels and then Western blotted with
antibodies specific for BCL11A or for the nuclear matrix marker lamin B.
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maximal repression. Similar results were observed for additional
non-B cell lines (NIH3T3, COS-7, andHeLa) andwere confirmed
by careful dose-response curves following transient cotransfection
(data not shown).
BCL11B, the highly similar paralogue of BCL11A (23), was
shown to interact with the nucleosome-remodeling and histone
deacetylase (NuRD) complex with enhanced repression of model
substrates (46). One of the NuRD components, metastasis tumor
antigen 1 (MTA1), was shown to interact with and enhance
BCL11B repression synergistically, while MTA2 had no effect
(46). We observed significant augmentation of BCL11A-XL re-
pression following cotransfection with MTA1 (Fig. 4B) but not
with MTA2 (data not shown). Conversely, enforced overexpres-
sion of BCL11A-XL with MTA1 in A70 pre-B cell lines had no
effect on activation of any of theRag1 orRag2 constructs (data not
shown).
We considered, as an alternative explanation for the opposite
effects in B versus non-B cells (other than B-lineage-specific co-
factors), a differential subcellular localization of BCL11A-XL. In B
cells, exogenous or ectopically overexpressed BCL11A-XL accu-
mulates primarily within the nuclear matrix of paraspeckles (30).
We observed localization indistinguishable from that following
ectopic delivery of GFP–BCL11A-XL or GFP–BCL11A-XL-K5/A
into 293T cells (Fig. 4C, top). Biochemical subcellular fraction-
ations (Fig. 4C, bottom) indicated that, as in B cells (30), wild-type
andmutant BCL11A-XL accumulate preferentially within the nu-
clear matrix.
The results suggest that BCL11A-XL acts in a context-depen-
dent, cell-type-specific mode to activate or repress RAG1 tran-
scription. The data further suggest that repressive BCL11A-XL
complexes differ from activation complexes by the inclusion/ex-
clusion of theMTA1 corepressor but are indistinguishable in their
subcellular localization.
BCL11A-XL induces ectopic V(D)J recombination in A70-
INV pre-B cells. The A70-INV Abl-transformed pre-B cell line
retains the properties of the parental A70 cell line, but it has been
engineered for inducible V(D)J recombination analysis by inte-
gration of a recombination substrate, pMX-INV, which, upon in-
version, activates expression of GFP (39). A70 and A70-INV also
constitutively express a Bcl2-E transgene, enabling them to sur-
vive apoptotic signaling for several days (39).We transducedA70-
INV cells with empty virus (pXY-puro) or with pXY-BCL11A-XL
and then puromycin selected bulk (uncloned) cells. As with A70
parental cells, BCL11A protein was barely detectable in untrans-
duced or mock-transduced A70-INV cells (Fig. 5A). Transduced
cells expressed significant levels of BCL11A-XL, resulting in ro-
bust induction of Rag1 and Rag2 (Fig. 5B).
The strategy used to detect the inversion of pMX-INV and V-J
recombination of the endogenous  light chain locus was de-
scribed previously (39) (Fig. 5C). As a positive control, strong
induction of recombination is achieved by treatment of A70-INV
cells with the Abl kinase inhibitor STI571 (47). STI571 causes
differentiation of early pre-B cells to a late-pre-B-cell-like state
(47). Strong Rag1 and Rag2 expression ensues, followed by V-J
recombination and, in A70-INV cells, inversion of the integrated
pMX-INV via cleavage at the flanking recombination signal se-
quences (RSSs) (Fig. 5C) (39). As shown in Fig. 5D, mock viral
transduction produced 0.7% and 18.1% GFP-positive cells with-
out or with STI571 treatment, respectively (Fig. 5DA and B). This
level of background GFP expression is similar to previously re-
ported data (39). BCL11A-XL-infected cells produced 7% and
34.5% GFP-positive cells without or with STI571 treatment, re-
spectively (Fig. 5DC and DD).
An10-fold increase in recombination substrate inversion by
BCL11A-XL in the absence of STI571 treatment suggested that
BCL11A-XL acts independently. Consistent with this interpreta-
tion, the level of substrate inversion by BCL11A-XL in the pres-
ence of STI571 was additive. Unlike the G1/S arrest induced by
STI571 treatment, BCL11A-XL transductionwas accompanied by
no alteration in cell cycling (as measured by DNA content of pro-
pidium iodide-stained cultures [data not shown]).
To verify that GFP expression resulted from inversion of pMX-
INV, we carried out semiquantitative PCR on genomic DNA us-
ing a 3= primer complementary to hCD4, a component of the
PMX-INVvectorwhich can be used to detect invertedGFP. pMX-
INV inversion allows successful PCR product formation by pro-
viding the reverse primer with the correct orientation of GFP
cDNA (Fig. 5C). As shown in Fig. 5E, an increase in the intensities
of inverted GFP-hCD4 PCR products was observed in STI571-
treated or BCL11A-XL-transduced cells compared to STI571-un-
treated or mock virus-transduced cells.
Modulation of BCL11A expression in transformed or nor-
mal murine pre-B cells modulates endogenous V(D)J recombi-
nation. Although integrated as a single copy, the pMX-INV re-
porter locus may not display the equivalent heterochromatin
structure as the endogenous light chain loci in pre-B cells. To
assess whether the endogenous locus can also be induced to rear-
range by BCL11A-XL overexpression, genomic DNA was ana-
lyzed by PCR using a “universal” V forward primer and J2-1
reverse primer (Fig. 6A, top). Efficient PCR can occur only if VJ
rearrangement deletes the intervening sequence between V and
J elements. VJ rearrangement was evaluated by Southern blot-
tingwith a J2-2 oligonucleotide probe (Fig. 6A). As shown in Fig.
6A (bottom), increased levels of J rearrangement were observed
in both STI571-treated (lanes 4 to 6) and BCL11A-XL-transduced
(lanes 10 to 12) cells compared to control cells.
To address the issue in normal developing B cells, we employed
mice with loxP (L) sites flanking exon1 of the Bcl11a gene
(Bcl11aL/L) (29, 35; Ippolito et al., submitted). Bone marrow cul-
tures were established as previously described (8, 36), by expand-
ing bead-purified B220 cells in culture with IL-7. In an effort to
delete Bcl11a, the cells were infected with either an empty vector
(MIT [mouse stem cell virus–internal ribosomal entry site–Thy-
1.1]) or the equivalent retrovirus which expresses Cre recombi-
nase (MIT-Cre).Within 3 days, theMIT-Cre-infected cells under-
went a proliferative block and apoptosis and died within 3 days
(data not shown). To overcome this and allow for sufficient num-
bers of viable cells to be harvested, we first transduced the cells
with a retrovirus (MSCV–Bcl-xL) that encodes the antiapoptotic
Bcl-xL factor and cultured these cells for 2 days prior to superin-
fection with either MIT or MIT-Cre. Proliferation was rescued in
theMIT-Cre cultures, and cells were collected 3 days after second-
ary infection for analysis.
It was essential for quantitative comparisons to determine the
percentage of B220 cells infected under both conditions. Taking
advantage of the Thy-1.1marker encoded in both vectors, we ob-
served by flow cytometry that control and Cre-deleted B220 B
cell progenitors showed comparable transduction efficiencies
(	75%) (Fig. 6B). Since MIT-Cre-infected cells required Bcl-xL
expression to bypass apoptosis, it was crucial to check their pro-
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liferative status, particularly since both V(D)J recombination and
RAG2 expression are regulated at the G1 phase of the cell cycle
(48). As shown in Fig. 6C, comparable cell cycle progression
within normal limits for diploid cells was observed for control and
Cre-deleted cultures.
To quantify the extent of Cre-mediated Bcl11aL/L deletion and
VJ reduction at the DNA level, we employed 5-fold dilutions of
genomic DNA analyzed by both semiquantitative and real-time
PCR by using the scheme shown in Fig. 6A. Figure 6D shows the
normalized, real-time fold reduction values, indicated under each
corresponding ethidium bromide-stained, semiquantitative PCR
band for theMIT-Cre condition (calculation is further detailed in
the legend). VJ rearrangement was strongly reduced (average of
15-fold) in direct correlation with Bcl11a deletion (22-fold).
This was paralleled by a dramatic reduction (13- to 19-fold) in
Rag1, Rag2, and Bcl11a transcript levels (Fig. 6E).
BCL11A-XL overexpression upregulates additional genes
implicated in V(D)J recombination and pro-pre-B cell progres-
sion. In addition to RAGs, transcription of several genes previ-
ously shown to encode proteins involved in V(D)J recombination
were modulated following BCL11A-XL overexpression in A70
pre-B cells (Fig. 7). Both interferon-regulatory factor 4 (IRF4) and
IRF8 were strongly upregulated by BCL11A-XL overexpression.
Upregulation of these transcription factors has been reported to
be essential for Ig light chain recombination (49). We also ob-
served consistent upregulation of Foxp1 and FoxO1, factors pre-
viously shown to activate RAG via binding to Erag (8, 11). Con-
versely, the Erag binding activators E2a and FoxO1 remained
unchanged. Ig germ line transcription, often observed as a con-
sequence of chromatin accessibility of the J locus (7), and the 5
chain of the pre-B cell receptor were unaffected, whereas its part-
ner subunit, Vpre-B, was strongly upregulated by BCL11A-XL.
Inspection of the ENCODE human B cell GM12878 ChIPseq data
for BCL11A (28) indicated strong binding peaks within 2 kb up-
or downstream of the transcriptional start sites of VpreB, FoxO1,
IRF8, and IRF4, suggesting that these loci are also directly targeted
by BCL11A.
Transcript modulation following STI571 treatment correlated
only modestly with that induced by BCL11A-XL overexpression,
further emphasizing the different mechanisms of these two RAG
activators. For example, and as observed for other Abelson pre-B
cell lines (6), STI571 induced expression of Spi-B and Ig germ
FIG 5 Enforced expression of BCL11A-XL in A70-INV pre-B cells induces V(D)J recombination. (A and B) Establishment of stable overexpression in A70-INV
pre-B cells. Transductions and drug selection are described in the legend of Fig. 4A. (A) Anti-Flag Western detection of ectopic BCL11A-XL and anti-BCL11A
immunoblotting detection of total expression of BCL11A-XL. -Tubulin served as a loading control. (B) Transduction of A70-INV cells with BCL11A-XL
upregulates RAG1 and RAG2 mRNA relative to mock-transduced cells. GAPDH was the loading control. (C) Schematic diagram of recombination signal
sequence (RSS) (black and white triangles)-mediated inversion within the integrated retroviral RAG substrate in A70-INV pre-B cells. Primers used to amplify
the inversion are denoted by arrows. (D) Flow cytometry detection of enhanced V(D)J recombination substrate inversion in A70-INV pre-B cells overexpressing
BCL11A-XL (XL) or treated with the Abelson kinase inhibitor STI571. Cells were transduced as described in the preceding figure legends and then incubated in
the absence (STI) or in the presence (STI) of STI571 at 3 M for 72 h. Inversion of pMX-INV resulted in GFP expression, which was quantified by
fluorescence-activated cell sorter analysis following exclusion of dead cells by forward- and side-scatter characteristics. The x axis shows GFP intensity; the y axis
shows cell numbers. Percentages of GFP-positive cells are noted in each plot. (E) PCR validation of RSS-mediated inversion of pMX-INV substrates. Genomic
DNA was isolated from the indicated cell lines for PCR according to the strategy and primers described above for panel C. STI571 (STI) treatment (3 M for 48
h) or transductionwith BCL11A-XL retrovirus induced inversion ofGFP, allowing PCR amplification (lanes 2 and 4). PCR amplification of the endogenousRag1
gene (which is unaffected by RSS-mediated recombination) provided a DNA loading control.
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line transcription (Fig. 7). However, in contrast to data from a
previous report (47), we observed robust STI571 repression of
IRF4 and IRF8 in A70 cells. Perhaps, the difference lies in the cell
lines employed. The previous results (47) were obtained with the
Abelson pre-B 200-8 line, which in our hands undergoes massive
cell death within 24 h of STI571 treatment (data not shown). The
constitutive expression of the Bcl2 transgene in A70 cells (39) al-
lowed us to analyze events even 4 to 6 days following STI571
treatment without cell death.
DISCUSSION
BCL11A was identified as a proto-oncogene implicated in multi-
ple B cell malignancies (26, 28, 29) and represents one of 200
“ultraconserved” genes in the human genome (19). Initially
thought to be exclusive to B cells, BCL11A is the first genetically
and functionally validated transcriptional regulator of both devel-
opmental control of globin switching and silencing of -globin
expression in humans (41, 50). While targeted knockout (25, 32)
identified Bcl11a as being essential for normal B cell development
in the mouse, the transcriptional mechanism and direct targets of
its action are incompletely understood.
We initially identified RAG1 as a potential target gene of the
major BCL11A isoform (BCL11A-XL) by microarray analysis
(Fig. 2A). Both it and RAG2 were confirmed by a combination of
BCL11A-XL overexpression and shRNA knockdown (Fig. 2B and
C). In principle, BCL11A-XLmight regulateRAG gene expression
FIG 6 Modulation of BCL11A expression modulates V(D)J rearrangement. (A) BCL11A-XL overexpression induces V-J recombination in A70-INV pre-B
cells. A degenerate V consensus primer (Vcon) and a J2-1 reverse primer (top) were used to amplify rearrangements from genomic DNA diluted in 3-fold
increments (triangles) to ensure nonsaturating semiquantitative PCR. The strategy predicted products of 190 bp (VJ2) and 540 bp (VJ1). Amplified DNAwas
resolved on agarose gels, transferred onto nylon membranes, and then visualized by autoradiography following hybridization to a J2-2 probe (top). (B) Flow
cytometric analysis of Bcl11aL/L bone marrow following primary infection with MSCV-Bcl-xL retrovirus and secondary superinfection with Thy-1.1-expressing
MIT or MIT-Cre retroviruses. Cells were stained with antibodies directly conjugated to phycoerythrin (PE-B220) and fluorescein isothiocyanate (FITC–Thy-
1.1). (C) Flow cytometric analysis of DNA content/cell cycle progression of Bcl11aL/L bonemarrow following the retroviral infection protocol detailed above for
panel B. Detergent-permeabilized cells were stained with propidium iodide and analyzed as described in Materials and Methods, using CellQuest software to
calculate percentages (denoted in right corners) of G1 (M1)-, G2/M (M2)-, and S (M1-M2 interval)-phase cells. (D) Cre recombinase-mediated deletion of
loxP-modified Bcl11a alleles (Bcl11aL/L) blocks V-J recombination in pre-B cell/IL-7 bone marrow (BM) cultures. Following retroviral infection, detailed as
described above for panel B, semiquantitative and real-time PCR of genomic DNA was performed on samples serially diluted 5-fold (triangles). DNA amplified
semiquantitatively was gel fractionated and visualized either directly by ethidium bromide staining (top and bottom) or following hybridization (middle), as
described above for panel A. PCRs of C served as loading controls. Real-time PCR values, shown as fold reduction (2) below corresponding lanes, were
determined for each DNA dilution by dividing each MIT control value by the corresponding MIT-Cre value. The analyses are representative of 4 independent
experiments performed with 4 separate BM isolates. (E) Rag1, Rag2, and Bcl11a transcript levels are significantly reduced following MIT-Cre-mediated deletion of
Bcl11aL/L in B220 BM pre-B cell cultures. Total RNA was converted to cDNA and subjected to amplification by semiquantitative RT-PCR or real-time quantitative
RT-PCR. cDNAwas serially diluted (triangles), fractionated, and analyzed as described above for panel B, with GAPDH dilutions serving as the control.
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either directly by interacting with cis-regulatory elements within
the RAG locus or indirectly by affecting other pathways that ulti-
mately impact RAG expression. To discriminate between these
possibilities, we observed both by BCL11A chromatin occupancy
and by in vitroDNAbinding using pro-B, pre-B, andmature B cell
lines that BCL11A was recruited to discrete regions of chromatin
within the RAG1 promoter and the Erag enhancer but not within
the RAG2 promoter (Fig. 1A and 3). Transcriptional reporter
studies in mouse pre-B cells suggested that two BCL11A binding
sites within the Rag1 promoter synergize to activate transcription
(Fig. 4B). The more promoter-distal BCL11A binding site con-
veyedmuch stronger (	4-fold) Erag enhancement (Fig. 4B). Fur-
ther consistent with the binding studies, BCL11A-XL failed to
drive Rag2 transcription unless Erag was appended to the con-
struct (Fig. 4B). High-resolution, genome-wide ChIPseq, derived
publically from the human B cell lymphoma GM12878 (28; http:
//www.factorbook.org/mediawiki/index.php/BCL11A) and from
the human pre-B ALL REH (our unpublished data), identified
BCL11A binding sites corresponding to those identified here (Fig.
3F) as well as several others scattered across the RAG locus (data
not shown). This, along with the finding (29, 35) that within the
expansive -globin locus, BCL11A tends to associate with distal
control elements rather than proximal promoters, prompts cau-
tion as to overly simplified conclusions of the relative importance
of any single BCL11A binding site within this complex regulatory
locus. The genome-wide ChIP data (28) further indicate that the
500 strongest BCL11A sites within the genome overlap PU.1 sites.
Similarly, equivalent genome-wide ENCODE data for PU.1
ChIPseq (28; http://www.factorbook.org/mediawiki/index.php
/PU.1) indicated with high statistical significance (P  1.011)
that a large proportion of PU.1 peaks are in close vicinity to
BCL11A peaks. Taken with our EMSA data shown in Fig. 3B, it is
highly probable that these factors broadly collaborate or antago-
nize transcription via closely spaced or even overlapping compos-
ite sites.
These findings, along with the observation that recombinant
BCL11A-XL failed to bind established target motifs in vitro,
prompted us to test the transcriptional consequences of enforced
BCL11A expression in non-B cells. Unexpectedly, we observed
strong repression of RAG1 promoter-driven transcription in epi-
thelial and fibroblast-derived cell lines, with the more promoter-
proximal BCL11A-XL binding site being sufficient to target the
activity (Fig. 4B and data not shown). In addition to suggesting
that a lineage-restricted cofactor(s) is required for BCL11A-XL to
transactivate RAG in lymphoid cells, potential physiologic rele-
vance is provided by the observations that the RAG1 promoter is
not lymphoid restricted (9, 12) and that RAG expression is ob-
served in several nonlymphoid malignant cell types (35, 48, 51–
54). Additional relevancemay be drawn from the observation that
Bcl11a expression within T lineages is limited to double-nega-
tive-2 (DN2) stage thymocytes, in which V(D)J recombination of
the TcR locus initiates (55). At DN3, Bcl11a is extinguished, and
expression of its highly similar paralogue, Bcl11b, ensues (56).
Although Bcl11b has not previously been implicated in Rag con-
trol, Bcl11b/ thymocytes are impaired in V-D recombina-
tion (57).
The domain responsible for both non-B cell repression and
pre-B cell activation of BCL11A-XL maps to the N terminus, as
deletion of the first 80 amino acids or a single-point mutation
(K5/A) within the highly conservedMSRRKmotif (Fig. 1B) abro-
gated both transcriptional activities while retaining normal
BCL11A-XL subnuclear localization (Fig. 4B and C and data not
shown). The N-terminal motif defines a superfamily of transcrip-
tion factors crucial to the development, differentiation, and ma-
lignancy of several hematopoietic lineages (Fig. 1B) (23, 26, 30, 45,
58). The N terminus, when extended to include the equally con-
served C2HC zinc finger (Fig. 1B), is required for BCL11A-XL to
dimerize with itself, with all other BCL11A isoforms (30), and with
several corepressor complexes, including NuRD, LSD1/CoREST,
NCoR/SMRT, and SIN3 (46, 51; data not shown). Consistent with
FIG 7 Comparison of BCL11A-XL overexpression with STI571 induction of V(D)J recombination-associated genes. A70-INV pre-B cells were treated with
STI571 (3 M for 20 h) or were stably transduced with BCL11A-XL (XL) or empty virus (V), as described in the legend of Fig. 4. (A) Semiquantitative RT-PCR
analysis. cDNAwas amplified under linear conditions, gel fractionated, and visualized by ethidium bromide staining of cDNA. GAPDHwas the loading control.
Asterisks denote transcripts that were consistently upregulated in at least 4 independent experiments. (B) Real-time quantitative RT-PCR analysis. Assays were per-
formed in triplicate and analyzed by the standard curvemethod (42, 43), by normalization to GAPDH. Fold changes for STI571 values are plotted relative to values for
untreated controls, and fold changes for BCL11A-XL values are plotted relative to empty vector (V) controls, with both controls arbitrarily set at a value of 1.
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this, we observed enhanced BCL11A-XL repression of RAG1
following coexpression with MTA1, a single member of the 12-
memberedNuRD complex, whichwe suspect to be limiting under
the conditions which we employed (Fig. 4B and data not shown).
Collectively, the results suggest that BCL11A’s N-terminal do-
main is employed in a context-dependent fashion for assembly of
both well-characterized corepressor complexes as well as coacti-
vation complexes whose members remain to be defined.
As anticipated, we observed modulation of V(D)J recombina-
tion proportional to BCL11A-XL overexpression in cultured A70
pre-B cells (Fig. 5 and 6A) or following Cre-mediated knockdown
in cultured explants of Bcl11aL/L bonemarrow-derived pre-B cells
(Fig. 6B and D). We suggest that the robustness of the effect,
particularly in normal pre-B cells that dominate the IL-7 cultures,
is derived from both direct transcriptional activation by
BCL11A-XL of the RAG locus and upregulation of additional
transcription factors that either perform the redundant function
or act to promote chromatin accessibility of the V(D)J locus (Fig.
7). Validated examples of the first group include FOXP1, which
transactivates RAG directly via binding to Erag (Fig. 1A and 3) (8,
11). Elevation and concerted action of this and similar factors that
upregulate RAG may be sufficient for the V-J inversion of the
exogenous recombination target pMX-INV (Fig. 5C and D). Ex-
amples of the second category, which have been shown to be re-
quired for chromatin accessibility of the endogenousV(D)J locus,
include IRF4 and IRF8 (Fig. 7). V(D)J recombination and B cell
development are blocked in IRF4/IRF8 double knockout mice at
the pre-B cell stage (49). Accessibility and recombination of V-J
has been correlated with selected posttranslational modifications
of nucleosomal histone (H) tails (59–61). Ectopic expression of
IRF4 in IRF4/8/ pre-B cells was shown to increase acetylation of
H3K9 and H4K14 as well as trimethylation of H3K4, marks asso-
ciated with active chromatin (49). However, induction of J-C
germ line transcription, a second feature typically but not always
(62) associated with locus accessibility, was not observed follow-
ing BCL11A-XL overexpression (Fig. 7). Perhaps, the concomi-
tant lack of BCL11A-XL upregulation of Spi-B (Fig. 7), which,
along with IRF4, has been reported to be sufficient for inducing
Ig germ line transcripts (36), is rate limiting under these condi-
tions. Resolution will require a careful assessment of BCL11A-
mediated germ line transcription and histone epigenetic altera-
tions across this locus.
Consistent with a recent report by Yu et al. (32), we observed
significantly reduced proliferation and increased apoptosis rela-
tive to controls in floxed cultures ofBcl11aL/LB220 bonemarrow
pre-B cells (Fig. 6 and data not shown). In further agreement with
that report (32), prior infection of Bcl11aL/L cells with a Bcl-xL-
encoding retrovirus bypassed Cre-mediated apoptosis and prolif-
eration. Bcl11a/ fetal liver hematopoietic progenitors suffer a
severe pre-pro-B cell block (57), typically as a consequence of a
proliferative defect in IL-7R signaling (63, 64) or a defect in V(D)J
recombination (6). The weight of data assembled here, along with
the observations (25, 32, 50, 55) that Bcl11a expression in mouse
hematopoiesis initiates at the hematopoietic stem cell stage, sug-
gests that the initial D-J recombination step of antigen receptor
assembly will be impaired by conditionalBcl11a deficiency. Itmay
be informative that Foxp1, a putative target of BCL11A-XL
(Fig. 7), activates this earliest RAG-mediated step of V(D)J joining
(11). Further in vivo studies in the context of potential collaborat-
ing transcription factors such as Foxp1 and PU.1 are required to
elucidate whether Bcl11a is, indeed, at the top of the hierarchy of
V(D)J transcriptional control.
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